CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial
July 16, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI trial costs DENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding...
SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 11, 2024 16:05 ET
|
SeaStar Medical Holding Corporation
DENVER, July 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that it has closed its previously announced registered offering for the...
SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
July 10, 2024 09:00 ET
|
SeaStar Medical Holding Corporation
DENVER, July 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), today announced it has entered into a definitive agreement for the issuance and sale of...
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
June 07, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
May 22, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE...
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
April 17, 2024 16:00 ET
|
SeaStar Medical Holding Corporation
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
April 11, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
March 27, 2024 08:30 ET
|
SeaStar Medical Holding Corporation
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
December 27, 2023 08:01 ET
|
PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition...
Lucid Diagnostics Announces Pricing of Initial Public Offering
October 13, 2021 22:15 ET
|
Lucid Diagnostics Inc.
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...